Re-evaluation of histological diagnoses of malignant mesothelioma by immunohistochemistry

Diagnostic Pathology

Volumn 5, Issue 1, 2010, Pages

  Sandeck, Helmut P ^a   Røe, Oluf D ^a   Kjærheim, Kristina ^b   Willén, Helena ^c   Larsson, Erik ^c,d,e  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b CANCER REGISTRY OF NORWAY   (Norway)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

PARAFFIN; TUMOR MARKER;

AGED; ARTICLE; AUTOPSY; BIOPSY; CHEMISTRY; DIAGNOSTIC ERROR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; MESOTHELIOMA; MIDDLE AGED; MORTALITY; NORWAY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; REGISTER; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; SURVIVAL RATE; TIME;

AGED; AUTOPSY; BIOPSY; DIAGNOSTIC ERRORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; MALE; MESOTHELIOMA; MIDDLE AGED; NORWAY; PARAFFIN EMBEDDING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REGISTRIES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 78649923900     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-5-47     Document Type: Article

References (48)

1. Takeshima Y, Inai K, Amatya VJ, Gemba K, Aoe K, Fujimoto N, Kato K, Kishimoto T. Accuracy of pathological diagnosis of mesothelioma cases in Japan: clinicopathological analysis of 382 cases. Lung Cancer 2009, 66:191-197. 10.1016/j.lungcan.2009.01.011, 19232771.
2. Kayser K. Analytical Lung Pathology 1992, Berlin etc., Springer-Verlag.
3. Churg A, Roggli V, Galateau-Sallé F, Cagle P, Gibbs AR, Hasleton P, Henderson DW, Vignaud JM, Inai K, Praet M, Ordóñez NG, Hammar SP, Testa JR, Gazdar AF, Saracci R, Pugatch R, Samet JM, Weill H, Rusch V, Colby TV, Vogt P, Brambilla E, Travis WD. Mesothelioma. Pathology and genetics of tumours of the lung, pleura, thymus and heart 2004, 128-136. WHO/IARC. Lyon, IARC Press, Travis WD, Brambilla E, Müller-Hermelink HK, Curtis CH.
4. Røe OD. Malignant mesothelioma: virus, biomarkers and genes: a translational approach. PhD Thesis. Norwegian University of Science and Technology, Faculty of Medicine, Institute of Cancer Research and Molecular Medicine & Institute of Laboratory Medicine, Children's and Women's Health, Trondheim 2008,
5. Røe OD, Anderssen E, Helge E, Pettersen CH, Olsen KS, Sandeck H, Haaverstad R, Lundgren S, Larsson E. Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype. PLoS ONE 2009, 4:e6554. 10.1371/journal.pone.0006554, 2717215, 19662092.
6. (ed) Pathology of malignant mesothelioma 2006, Springer, London, (ed).
7. Butnor KJ, Sporn TA, Ordóñez NG, . Association of Directors of Anatomic and Surgical Pathology (ADASP) Recommendations for the reporting of pleural mesothelioma. Virchows Arch 2007, 450:15-23. 10.1007/s00428-006-0301-7, 17334801, Association of Directors of Anatomic and Surgical Pathology (ADASP).
8. Okada M, Mimura T, Ohbayashi C, Sakuma T, Soejima T, Tsubota N. Radical surgery for malignant pleural mesothelioma: results and prognosis. Interact Cardiovasc Thorac Surg 2008, 7:102-106. 10.1510/icvts.2007.166322, 18048410.
9. Borasio P, Berruti A, Bille A, Lausi P, Levra MG, Giardino R, Ardissone F. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients. Eur J Cardiothorac Surg 2008, 33:307-313. 10.1016/j.ejcts.2007.09.044, 18164622.
10. Ceresoli GL, Locati LD, Ferreri AJM, Cozzarini C, Passoni P, Melloni G, Zannini P, Bolognesi A, Villa E. Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer 2001, 34:279-287. 10.1016/S0169-5002(01)00257-4, 11679187.
11. Røe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjrheim K. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. Lung Cancer 2008, 61:235-243. 10.1016/j.lungcan.2007.12.025, 18281122.
12. Cancer Registry of Norway Cancer in Norway 2007 - Cancer incidence, mortality, survival and prevalence in Norway. Oslo 2008, Cancer Registry of Norway., http://www.kreftregisteret.no/no/Registrene/Kreftstatistikk
13. Ulvestad B, Kjaerheim K, Møller B, Andersen A. Incidence trends of mesothelioma in Norway, 1965-1999. International Journal of Cancer 2003, 107:94-98.
14. Larsen IK, Småstuen M, Johannesen TB, Langmark F, Parkin DM, Bray F, Møller B. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer 2009, 45:1218-1231. 10.1016/j.ejca.2008.10.037, 19091545.
15. Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, Dienemann H, Galateau-Salle F, Hennequin C, Hillerdal G, Le Péchoux C, Mutti L, Pairon JC, Stahel R, van Houtte P, van Meerbeeck J, Waller D, Weder W. ERS/ESTS Task Force Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010, 35:479-495. 10.1183/09031936.00063109, 19717482.
16. Walker C, Rutten F, Yuan X, Pass H, Mew DM, Everitt J. Wilms' tumor suppressor gene expression in rat and human mesothelioma. Cancer Res 1994, 54:3101-3106.
17. Amin KM, Litzky LA, Smythe WR, Mooney AM, Morris JM, Mews DJY, Pass HI, Csaba K, Rodeck U, Rauscher FJ, Kaiser LR, Albeida SM. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 1995, 146:344-356. 1869867, 7856747.
18. Gotzos V, Vogt P, Celio MR. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. Pathol Res Pract 1996, 192:137-147.
19. Doglioni C, Dei AP, Laurino L, Iuzzolino P, Chiarelli C, Celio MR, Viale G. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996, 20:1037-1046. 10.1097/00000478-199609000-00001, 8764740.
20. Kimura N, Kimura I. Podoplanin as a marker for mesothelioma. Pathol Int 2005, 55:83-86. 10.1111/j.1440-1827.2005.01791.x, 15693854.
21. Ordóñez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol 2005, 36:372-380. 10.1016/j.humpath.2005.01.019, 15891998.
22. Sonne SB, Herlihy AS, Hoei-Hansen CE, Nielsen JE, Almstrup K, Skakkebæk NE, Marks A, Leffers H, Rajpert-De Meyts E. Identity of M2A (D2-40) antigen and gp36 (Aggrus, T1A-2, podoplanin) in human developing testis, testicular carcinoma in situ and germ-cell tumours. Virchows Arch 2006, 449:200-206. 10.1007/s00428-006-0223-4, 16736189.
23. Husain AN, Colby TV, Ordóñez NG, Krausz T, Borczuk A, Cagle PT, Chirieac LR, Churg A, Galateau-Salle F, Gibbs AR, Gown AM, Hammar SP, Litzky LA, Roggli VL, Travis WD, Wick MR. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009, 133:1317-1331.
24. Kjærheim K, Røe OD, Waterboer T, Sehr P, Rizk R, Dai HY, Sandeck H, Larsson E, Andersen A, Boffetta P, Pawlita M. Absence of SV40 antibodies or DNA fragments in prediagnostic mesothelioma serum samples. International Journal of Cancer 2007, 120:2459-2465.
25. Dako Corporation REAL™ EnVision™ Detection System, Peroxidase/DAB+, Rabbit/Mouse. Kode K5007. 2008, 3, objectid= 1059 95004 Glostrup, Dako Corporation., http://www.dako.dk/prod_downloadpackageinsert.pdf?objectid=105995004
26. Laga AC, Allen T, Bedrossian C, Murer B, Cagle P. Diffuse malignant mesothelioma. Color atlas and text of pulmonary pathology 2005, Philadelphia, Lippincott Williams & Wilkins, Cagle PT.
27. King JE, Thatcher N, Pickering CA, Hasleton PS. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology 2006, 48:223-32. 10.1111/j.1365-2559.2005.02331.x, 16430468.
28. Yaziji H, Battifora H, Barry TS, Hwang HC, Bacchi CE, McIntosh MW, Kussick SJ, Gown AM. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol 2006, 19:514-23. 10.1038/modpathol.3800534, 16554731.
29. Wick MR, Loy T, Mills SE, Legier JF, Manivel JC. Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: a histochemical, ultrastructural, and immunohistologic study of 103 cases. Hum Pathol 1990, 21:759-66. 10.1016/0046-8177(90)90036-5, 2193875.
30. Ordóñez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Modern Pathology 2003, 16:192-197. (2003a), 10.1097/01.MP.0000056981.16578.C3, 12640097.
31. Brockstedt U, Gulyás M, Dobra K, Dejmek A, Hjerpe A. An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma. Am J Clin Pathol 2000, 114:203-209. 10.1309/QHCA-8594-TA7P-0DVQ, 10941335.
32. Roberts F, McCall AE, Burnett RA. Malignant mesothelioma: a comparison of biopsy and postmortem material by light microscopy and immunohistochemistry. J Clin Pathol 2001, 54:766-770. 1731284, 11577123.
33. Langseth H, Gislefoss RE, Martinsen JI, Stornes A, Lauritzen M, Andersen A, Jellum E, Dillner J. The Janus Serum Bank. From sample collection to cancer research. Oslo, Cancer Registry of Norway 2009, http://www.kreftregisteret.no/Global/29-01-2010%20CIN_2008_Special_Issue_Janus_Web.pdf
34. Comin CE, Dini S, Novelli L, Santi R, Asirelli G, Messerini L. h-Caldesmon, a useful positive marker in the diagnosis of pleural malignant mesothelioma, epithelioid type. Am J Surg Pathol 2006, 30:463-469. 10.1097/00000478-200604000-00006, 16625092.
35. Comin CE, Saieva C, Messerini L. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol 2007, 31:1139-1148. 10.1097/PAS.0b013e318033e7a8, 17667535.
36. Kayser K, Böhm G, Blum S, Beyer M, Zink S, André S, Gabius HJ. Glyco-and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients. J Pathol 2001, 193(2):175-80. 10.1002/1096-9896(2000)9999:9999<::AID-PATH772>3.0.CO;2-T, 11180163.
37. Knuuttila A, Jee KJ, Taskinen E, Wolff H, Knuutila S, Anttila S. Spindle cell tumours of the pleura: a clinical, histological and comparative genomic hybridization analysis of 14 cases. Virchows Arch 2006, 448:135-141. 10.1007/s00428-005-0059-3, 16170537.
38. Savic S, Bubendorf L. Fluoreszenz-in-situ-Hybridisierung. Eine neue diagnostische Dimension in der Zytologie. [Fluorescence in situ hybridisation. A new diagnostic dimension in cytology.]. Pathologe 2007, 28:384-392. 10.1007/s00292-007-0930-x, 17661041.
39. Ordóñez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod Pathol 2006, 19:34-48. 10.1038/modpathol.3800471, 16056246.
40. Ordóñez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003, 27:1418-1428. (2003b), 10.1097/00000478-200308000-00001, 14576474.
41. Kayser K. Personal written communication. June 19, 2006. 2006, (Permission to citation was given by the author to HS on Sept. 4, 2009 in Florence, ESP congress.).
42. German Mesothelioma Registry Mesotheliome. Pictures of three subtypes. Bochum 2010, German Mesothelioma Registry., http://www.bergmannsheil.de/index.php?id=788&L=1
43. Di Loreto C, Puglisi F, Di Lauro V, Damante G, Beltrami CA. TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung. Cancer Lett 1998, 124:73-78. 10.1016/S0304-3835(97)00466-7, 9500194.
44. Blobel GA, Moll R, Franke WW, Kayser KW, Gould VE. The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance. Am J Pathol 1985, 121:235-247. 1888049, 2414994.
45. Moll R. Cytokeratine als Differenzierungsmarker: Expressionsprofile von Epithelien und epithelialen Tumoren [Cytokeratins as markers of differentiation: Expression profiles of epithelia and epithelial tumours]. 1993, Stuttgart/Jena/New York, G. Fischer Verlag.
46. Suster S, Moran CA. Applications and limitations of immunohistochemistry in the diagnosis of malignant mesothelioma. Adv Anat Pathol 2006, 13:316-329. 10.1097/01.pap.0000213064.05005.64, 17075297.
47. Winstanley AM, Landon G, Berney D, Minhas S, Fisher C, Parkinson MC. The immunohistochemical profile of malignant mesotheliomas of the tunica vaginalis: a study of 20 cases. Am J Surg Pathol 2006, 30:1-6. 10.1097/01.pas.0000178094.07513.71, 16330935.
48. Marchevsky AM, Wick MR. Evidence-based guidelines for the utilization of immunostains in diagnostic pathology: pulmonary adenocarcinoma versus mesothelioma. Appl Immunohistochem Mol Morphol 2007, 15:140-144. 10.1097/01.pai.0000213148.62525.9a, 17525624.